Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Asuragen introduces new QuantideX NGS RNA lung cancer kit

MDBR Staff Writer Published 02 November 2016

Molecular diagnostics firm Asuragen has introduced next generation QuantideX NGS RNA lung cancer kit.

The new sequencing panel can study known clinically-relevant gene fusions, 3’/5’ imbalance markers, exon skipping events, and mRNA expression levels in non-small cell lung cancer (NSCLC) samples.

QuantideX RNA lung cancer kit, which is an end-to-end NGS-in-a-Box product solution, has been developed for use with low-quality and quantity samples such as FFPE and fine-needle aspirations.

The sensitive assay can detect fusions and splice variants at 5% and 1% cell fractions.

With its integrated workflow, the kit can deliver sequencing-ready libraries in around half the time of compared to competitor methods and and incorporates push-button analytics that standardize results.

According to the firm, the assay is for research use only and cannot be used in diagnostic procedures.

The firm’s Sample-Aware bioinformatics software solution is said to minimize the subjective results commonly associated with less integrated product offerings currently on market

Asuragen president and CEO Dr Matthew McManus said: “With the release of this new RNA-Seq assay, Asuragen is providing the most comprehensive and sensitive research tool for examining  >100 clinically-relevant NSCLC gene rearrangements across 11 different fusion partners.”

“In providing an integrated and comprehensive workflow solution, Asuragen’s NGS assays reduce the barrier-to-entry for laboratories considering targeted NGS oncology assays while also providing new options for laboratories already familiar with NGS technology.”

Asuragen also produces Quantidex pan cancer kit, which is a workflow solution for targeted next-generation sequencing (NGS). It incorporates reagents, controls and bioinformatics suite for the sequencing of 21 genes relevant to a diverse set of human cancers.

Quantidex pan cancer kit was developed to examine difficult sample types such as formalin-fixed paraffin embedded (FFPE) and fine-needle aspiration (FNA) tissues.